- Previous Close
31.10 - Open
30.77 - Bid 22.07 x 100
- Ask 38.09 x 100
- Day's Range
29.65 - 31.07 - 52 Week Range
18.61 - 47.32 - Volume
710,113 - Avg. Volume
926,805 - Market Cap (intraday)
2.348B - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
97.16 - EPS (TTM)
0.31 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.50
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
www.veracyte.com824
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VCYT
View MorePerformance Overview: VCYT
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VCYT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VCYT
View MoreValuation Measures
Market Cap
2.35B
Enterprise Value
2.11B
Trailing P/E
97.16
Forward P/E
24.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.28
Price/Book (mrq)
2.00
Enterprise Value/Revenue
4.73
Enterprise Value/EBITDA
42.86
Financial Highlights
Profitability and Income Statement
Profit Margin
5.42%
Return on Assets (ttm)
1.39%
Return on Equity (ttm)
2.17%
Revenue (ttm)
445.76M
Net Income Avi to Common (ttm)
24.14M
Diluted EPS (ttm)
0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
289.44M
Total Debt/Equity (mrq)
4.31%
Levered Free Cash Flow (ttm)
66.49M